EXEL Updates STELLAR-303 Trial
Exelixis provides update on the Phase 3 STELLAR-303 trial evaluating Zanzalintinib in combination with an immune checkpoint inhibitor in patients with metastatic colorectal cancer
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.